Literature DB >> 21741478

Twice switched at birth: cell cycle-independent roles of the "neuron-specific" cyclin-dependent kinase 5 (Cdk5) in non-neuronal cells.

Johanna Liebl1, Robert Fürst, Angelika M Vollmar, Stefan Zahler.   

Abstract

Cdk5 (cyclin-dependent kinase 5 or initially NCLK for neuronal CDC2-like kinase) was switched twice at its birth nearly twenty years ago: first it was thought to be cyclin-dependent, second it was assumed to be primarily of importance in neuronal cells-both turned out not to be the case. In this review we want to discuss issues of pharmacological inhibition, to highlight the versatile roles, and to summarize the growing evidence for the functional importance of Cdk5 in non-neuronal tissues, such as blood cells, tumor cells, epithelial cells, the vascular endothelium, testis, adipose and endocrine tissues. The organizing principles we follow are apoptosis/cell death, migration/motility, aspects of inflammation, and, finally, secretion/metabolism.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21741478     DOI: 10.1016/j.cellsig.2011.06.020

Source DB:  PubMed          Journal:  Cell Signal        ISSN: 0898-6568            Impact factor:   4.315


  30 in total

1.  Anti-angiogenic effects of novel cyclin-dependent kinase inhibitors with a pyrazolo[4,3-d]pyrimidine scaffold.

Authors:  S Zhang; M Ulrich; A Gromnicka; L Havlíček; V Kryštof; R Jorda; M Strnad; A M Vollmar; S Zahler
Journal:  Br J Pharmacol       Date:  2016-07-24       Impact factor: 8.739

2.  Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models.

Authors:  Chaoxin Hu; Tikva Dadon; Venugopal Chenna; Shinichi Yabuuchi; Rajat Bannerji; Robert Booher; Peter Strack; Nilofer Azad; Barry D Nelkin; Anirban Maitra
Journal:  Mol Cancer Ther       Date:  2015-04-30       Impact factor: 6.261

3.  Cyclin-dependent kinase 5 phosphorylation of familial prion protein mutants exacerbates conversion into amyloid structure.

Authors:  Raphaël Rouget; Gyanesh Sharma; Andréa C LeBlanc
Journal:  J Biol Chem       Date:  2015-01-08       Impact factor: 5.157

4.  Heat shock inhibition of CDK5 increases NOXA levels through miR-23a repression.

Authors:  Trevor M Morey; Rabih Roufayel; Donald S Johnston; Andrew S Fletcher; Dick D Mosser
Journal:  J Biol Chem       Date:  2015-03-31       Impact factor: 5.157

5.  Cdk5 controls lymphatic vessel development and function by phosphorylation of Foxc2.

Authors:  Johanna Liebl; Siwei Zhang; Markus Moser; Yan Agalarov; Cansaran Saygili Demir; Bianca Hager; James A Bibb; Ralf H Adams; Friedemann Kiefer; Naoyuki Miura; Tatiana V Petrova; Angelika M Vollmar; Stefan Zahler
Journal:  Nat Commun       Date:  2015-06-01       Impact factor: 14.919

Review 6.  The Emerging Role of Cdk5 in Cancer.

Authors:  Karine Pozo; James A Bibb
Journal:  Trends Cancer       Date:  2016-10

7.  Proteomic analysis of the human cyclin-dependent kinase family reveals a novel CDK5 complex involved in cell growth and migration.

Authors:  Shuangbing Xu; Xu Li; Zihua Gong; Wenqi Wang; Yujing Li; Binoj Chandrasekharan Nair; Hailong Piao; Kunyu Yang; Gang Wu; Junjie Chen
Journal:  Mol Cell Proteomics       Date:  2014-08-05       Impact factor: 5.911

8.  Cdk5 promotes DNA replication stress checkpoint activation through RPA-32 phosphorylation, and impacts on metastasis free survival in breast cancer patients.

Authors:  Sara Chiker; Vincent Pennaneach; Damarys Loew; Florent Dingli; Denis Biard; Fabrice P Cordelières; Simon Gemble; Sophie Vacher; Ivan Bieche; Janet Hall; Marie Fernet
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

9.  First Step in Catalysis of the Radical S-Adenosylmethionine Methylthiotransferase MiaB Yields an Intermediate with a [3Fe-4S]0-Like Auxiliary Cluster.

Authors:  Bo Zhang; Arthur J Arcinas; Matthew I Radle; Alexey Silakov; Squire J Booker; Carsten Krebs
Journal:  J Am Chem Soc       Date:  2020-01-16       Impact factor: 15.419

10.  Trisubstituted pyrazolopyrimidines as novel angiogenesis inhibitors.

Authors:  Sabine B Weitensteiner; Johanna Liebl; Vladimir Krystof; Libor Havlíček; Tomáš Gucký; Miroslav Strnad; Robert Fürst; Angelika M Vollmar; Stefan Zahler
Journal:  PLoS One       Date:  2013-01-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.